Press release from Companies
Published: 2025-08-21 08:30:00
The Company has advanced well with its planned activities
Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 April – 30 June 2025. The second quarter report is available as an attached document to this press release and on www.cessatech.com under Investor/Filings & Reports.
Second quarter financial results 2025 (1 April – 30 June):
Earnings per share (DKK per share): Operating result divided by the average number of shares during the period. The total number of shares as of 30 June 2025 amounted to 18.576.437 shares, the average number of shares during the second quarter was 17.680.598
**Solidity: Total equity divided by total capital and liability
Comments from CEO, Jes Trygved:
Recent highlights include significant operational and regulatory advancements, with the US manufacturing tech-transfer nearing completion and the CT001 dossier actively being developed for EMA submission. To support this growth, the organisation has been strengthened through the promotion of Martin Juhl to the Executive Management team, and our financial position has been fortified by a recent directed issue of DKK 14.6 million. The positive top-line results from Study 0202 represent a critical milestone, forming a key component of our regulatory submissions and future partner commercial activities. Thanks for a great effort by the team !
For more information about Cessatech, please contact:
Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com
About Cessatech
Cessatech A/S is a Danish pharmaceutical company committed to developing and commercialising evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute pain management in children. Another key asset of Cessatech is CT002, which is at the early development phase, for sedative procedures.